France Archives

News and Trends 17 May 2017

A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval

Cinfa Biotech announced trial results for a biosimilar of Amgen’s Neulasta, a multi-billion blockbuster to treat chemotherapy-induced neutropenia. Cinfa Biotech is a Spanish company specialized in developing biosimilars. The biotech has announced positive results from the second clinical trial evaluating a biosimilar version of Neulasta (pegfilgrastim), Amgen’s second top-selling drug. It brought the big pharma €4.2Bn in […]

May 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Noxxon Merck checkpoint inhibitor combination

News and Trends 16 May 2017

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12 with checkpoint inhibitor Keytruda. Based in Berlin, Noxxon is yet another biotech looking to bolster the success of checkpoint inhibitors by combining them with its ‘next-generation’ immuno-oncology candidates. The company partnered up with Merck & Co. […]

May 16, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 15 May 2017

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic and fibrotic diseases and cancer. Now the company has cleared its first Phase I trial for its lead candidate ISTH0036 in […]

May 15, 2017 - 2 minutesmins - By Melanie De Almeida

Seuss Recruitment life sciences time money

News and Trends 15 May 2017

How to Save Time and Money when Recruiting in the Life Sciences

The right hiring choice can bring huge benefits to the growth of a life sciences company. How can you make the best decision while saving time and money? In Europe, a bad hire costs employers an average of almost €60,000, starting with a minimum of €6,000 that rapidly escalates with the seniority of the role […]

May 15, 2017 - 4 minutesmins - By External Contributor

Interview 15 May 2017

Meet the CEO developing the Next Generation of Antibody Therapeutics

Crescendo Biologics has positioned itself as the successor of Cambridge Antibody Technology and a new rival to Morphosys. We interviewed CEO Peter Pack. Peter Pack started working in life science 25 years ago — “quite a long time ago,” he laughs. “I’m an old guy now.” Now the CEO of Crescendo Biologics, whose Humabody platform […]

May 15, 2017 - 8 minutesmins - By Evelyn Warner

Rebecca Harris Symbiosis Invisible You Microbiome

News and Trends 13 May 2017

Visualizing the Microbiome through Handmade Embroidery

Rebecca Harris is a British artist that uses handmade embroidery to visually communicate the huge diversity of microbes that form part of our bodies. Trillions of microbes live on us and inside us. “Microbes are essential for our well-being and development. The microbes stimulate and develop the immune response, and they detoxify harmful carcinogenic compounds in our […]

May 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 May 2017

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […]

May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

fossil proteins virus resistance granada

News and Trends 12 May 2017

Resurrected Proteins could be New Weapon against Crop Viruses

Researchers from Spain have succeeded in expressing a 4 billion year-old enzyme in a present-day E. coli. It’s similar enough to the modern version to work, but different enough to dupe viruses. A new way to create virus resistance in crops? In a lab at the University of Granada, Spain, that specializes in reconstructing ancient gene sequences, researchers have […]

May 12, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 12 May 2017

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […]

May 12, 2017 - 2 minutesmins - By Evelyn Warner

Celyad heart failure cell therapy C Cure

News and Trends 11 May 2017

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy

Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […]

May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 11 May 2017

Video: Meet the CEO developing Gene Therapy without Viral Vectors

Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment options in the field of ophthalmology. The biotech has developed a new gene therapeutic approach that […]

May 11, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 11 May 2017

HIV Treatment Development Extends Life Expectancy by 10 Years

According to a new study, the life expectancy of 20-year-olds starting HIV treatment has increased by a decade in the EU and North America. A massive new study from the UK was published today in The Lancet HIV. The study tracked how many HIV patients died during the first three years of HIV treatment, their cause […]

May 11, 2017 - 3 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

France

A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

How to Save Time and Money when Recruiting in the Life Sciences

Meet the CEO developing the Next Generation of Antibody Therapeutics

Visualizing the Microbiome through Handmade Embroidery

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Resurrected Proteins could be New Weapon against Crop Viruses

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy

Video: Meet the CEO developing Gene Therapy without Viral Vectors

HIV Treatment Development Extends Life Expectancy by 10 Years

Subscribe to our newsletter to get the latest biotech news!